ArticlePakistan journal of medical sciences2026
Comparison of efficacy of intravenous versus intramuscular injection meglumine antimoniate in patients of cutaneous leishmaniasis.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy of intravenous versus intramuscular meglumine antimoniate in the treatment of cutaneous leishmaniasis. Methodology: This randomized controlled trial was carried out in Dermatology Department of Tertiary Care Hospital, Quetta, from April to October 2024. Patients with biopsy proven cutaneous leishmaniasis were randomized into intravenous and intramuscular groups. The intravenous group received 15mg/kg/day of meglumine antimoniate diluted in 100 ml of 5% glucose solution over 60 minutes, while the intramuscular group received a similar dose into gluteal muscles. All patients were observed for treatment response at 15, 30, 45 and 60 days of treatment unless cured. Results: Ninety patients were divided into two groups of 45 each. Participants mean age was 30.10±5.75 years. The mean number of lesions were 4.28±3.67. The mean number of injections was 36.91±8.296. Intravenous group patients demonstrated early recovery with mean number of injections 28.78±2.57 in comparison to that in intramuscular group 39.56±2.80, this difference in efficacy was statistically significant (p<0.001). Pain at the injection site was significantly lower in the intravenous group compared to the intramuscular group (p<0.05). Conclusion: Intravenous administration of injection meglumine antimoniate is superior to Intramuscular in terms of enhanced efficacy and improved patient outcome. There were statistically insignificant side effects between two groups except for pain at injection site which was more with intramuscular route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.